^
    1d
    Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (clinicaltrials.gov)
    P=N/A, N=350, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (clinicaltrials.gov)
    P2, N=18, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025
    Trial completion date
    |
    PTEN (Phosphatase and tensin homolog) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    PTEN expression • TSC1 mutation • TSC2 mutation
    |
    samotolisib (LY3023414)
    1d
    Chidamide Plus Golidocitinib in Relapsed/Refractory Peripheral T-Cell Lymphoma (clinicaltrials.gov)
    P1/2, N=45, Not yet recruiting, Peking University Cancer Hospital & Institute
    New P1/2 trial
    |
    Epidaza (chidamide) • golidocitinib (DZD4205)
    1d
    Phase II Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to Chemotherapy (clinicaltrials.gov)
    P2, N=50, Recruiting, First Affiliated Hospital of Ningbo University
    New P2 trial
    |
    Epidaza (chidamide)
    1d
    Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis (clinicaltrials.gov)
    P2/3, N=50, Recruiting, Federal Research Institute of Pediatric Hematology, Oncology and Immunology
    New P2/3 trial
    |
    Jakafi (ruxolitinib) • cyclophosphamide • etoposide IV • fludarabine IV • Ovastat (treosulfan) • Entyvio (vedolizumab)
    1d
    PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=150, Recruiting, Ruijin Hospital
    New trial
    |
    GZMB (Granzyme B)
    1d
    Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, City of Hope Medical Center | Trial completion date: Sep 2024 --> Jun 2025
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • CD34 (CD34 molecule)
    1d
    A Study of Enasidenib in People With T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Rituxan (rituximab) • Idhifa (enasidenib)
    1d
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1)
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    1d
    CAPCI: CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01) (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Nordic Lymphoma Group
    New trial
    1d
    Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
    P1, N=48, Enrolling by invitation, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Enrolling by invitation | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Dec 2025
    Enrollment status • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD20 negative
    |
    CB CAR-NK019
    1d
    NCI-2018-00432: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases (clinicaltrials.gov)
    P2, N=9, Terminated, University of Washington | Trial completion date: Apr 2026 --> Aug 2024 | Active, not recruiting --> Terminated; Closed per SRC Low Accrual Policy.
    Trial completion date • Trial termination
    |
    Keytruda (pembrolizumab)
    1d
    17-BI-1206-02: A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL (clinicaltrials.gov)
    P1/2, N=140, Recruiting, BioInvent International AB | N=98 --> 140 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CRP (C-reactive protein)
    |
    Calquence (acalabrutinib) • Rituxan Hycela (rituximab/hyaluronidase) • BI-1206
    1d
    Telehealth Exercise Intervention to Improve Cardiovascular Health in Lymphoma Survivors, TECHS Trial (clinicaltrials.gov)
    P=N/A, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Oct 2024 --> Jun 2025 | Trial primary completion date: Oct 2024 --> Jun 2025
    Trial completion date • Trial primary completion date
    1d
    Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington University School of Medicine | N=40 --> 24
    Enrollment change
    |
    Lunsumio (mosunetuzumab-axgb)
    3d
    CAPCI: CtDNA for Early Response Assessment in PCNSL Treated with 1st Line Curative Intent (NLG-PCNSL-01) (clinicaltrials.gov)
    P=N/A, N=60, Recruiting, Nordic Lymphoma Group
    New trial
    3d
    NCI-2018-00432: Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases (clinicaltrials.gov)
    P2, N=9, Terminated, University of Washington | Trial completion date: Apr 2026 --> Aug 2024 | Active, not recruiting --> Terminated; Closed per SRC Low Accrual Policy.
    Trial completion date • Trial termination
    |
    Keytruda (pembrolizumab)
    3d
    FIL_Copa-RB: Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Terminated, Fondazione Italiana Linfomi - ETS | Active, not recruiting --> Terminated; low enrollment rate
    Trial termination
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6)
    |
    CD20 positive • BCL6 rearrangement • BCL2 rearrangement
    |
    Rituxan (rituximab) • Aliqopa (copanlisib) • bendamustine
    3d
    A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Hoffmann-La Roche | Trial completion date: Jan 2030 --> Sep 2029
    Trial completion date
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Actemra IV (tocilizumab) • Columvi (glofitamab-gxbm)
    3d
    Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma (clinicaltrials.gov)
    P2, N=37, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Trial primary completion date: Mar 2026 --> Dec 2026
    Trial primary completion date
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IFNA1 (Interferon Alpha 1)
    |
    azacitidine • prednisone • Epidaza (chidamide) • Duoenda (mitoxantrone liposomal)
    3d
    The Prognostic Predictive Value of TP53 mutation Variant Allele Frequency in Diffuse Large B-Cell Lymphoma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    TP53 mutation VAF has prognostic value in DLBCL patients, and TP53 mutation VAF≥34% is an independent risk factor for OS in DLBCL patients. The prognosis model of TP53 mutation VAF combined with IPI nomogram constructed in this study has good predictive performance for DLBCL patients.
    Journal
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    3d
    SOD1 Inhibitor LCS-1 Induces Apoptosis in Diffuse Large B-Cell Lymphoma Cells (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The expression levels of SOD1 in tumor tissues of DLBCL patients were significantly increased. As a SOD1 inhibitor, LCS-1 can significantly inhibit the viability and proliferation of DLBCL cell lines OCI-Ly18 and OCI-Ly19, and promote cell apoptosis, which provides a new idea for the treatment of DLBCL.
    Journal
    |
    LY9 (Lymphocyte Antigen 9) • SOD1 (Superoxide Dismutase 1)
    3d
    Clinical Features and Prognosis of Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    Primary EN-DLBCL can involve multiple organs or tissue sites. TP53 , MYD88 , and CD79B are the most common gene mutations. The efficacy of BTKi in patients with positive MCD subtypes at intermediate and high risk is not inferior to that in MCD-negative control patients.
    Retrospective data • Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule)
    |
    TP53 mutation • BCL2 expression • MYC expression • CD79B mutation • CD79B mutation
    |
    Rituxan (rituximab) • lenalidomide
    3d
    Influence of Methylenetetrahydrofolate Reductase C677T Polymorphism on High-Dose Methotrexate Toxicity in Pediatric Mature B-cell lymphoma Patients (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The risk of developing oral mucositis in children with mature B-cell lymphoma is associated with plasma MTX concentration. Polymorphism of MTHFR C677T gene is not related to plasma MTX concentration in children with mature B-cell lymphoma, but is related to grade III to IV hematological toxicity.
    Journal
    |
    MTHFR (Methylenetetrahydrofolate Reductase)
    |
    MTHFR C677T
    |
    methotrexate • methotrexate IV
    3d
    Clinical Study of Cord Blood-derived CAR-NK Cells Targeting CD19 in the Treatment of Refractory/Relapsed B-cell NHL (clinicaltrials.gov)
    P1, N=48, Enrolling by invitation, Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting --> Enrolling by invitation | Trial completion date: Sep 2025 --> Dec 2026 | Trial primary completion date: Sep 2023 --> Dec 2025
    Enrollment status • Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    CD19 expression • CD20 negative
    |
    CB CAR-NK019
    3d
    Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma (clinicaltrials.gov)
    P1, N=24, Recruiting, Washington University School of Medicine | N=40 --> 24
    Enrollment change
    |
    Lunsumio (mosunetuzumab-axgb)
    4d
    MicroRNAs and long non-coding RNAs In T-cell lymphoma: Mechanisms, pathway, therapeutic opportunities. (PubMed, Pathol Res Pract)
    Additionally, we explore the evolving function of non-coding RNAs in the pathogenesis of T-cell lymphoma. Furthermore, we discuss the potential of RNA-based therapeutics as a promising treatment strategy.
    Review • Journal • IO biomarker
    |
    MIR155 (MicroRNA 155) • MIR17HG (MiR-17-92a-1 Cluster Host Gene) • MIR17 (MicroRNA 17) • MIR223 (MicroRNA 223) • MIR31 (MicroRNA 31) • MIR150 (MicroRNA 150) • MIR29A (MicroRNA 29a)
    |
    miR-155 expression
    4d
    Mercuric chloride induced reproductive toxicity associated with oxidative damage in male Wistar albino rat, Rattus norvegicus. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    All the evidence suggests that after mercury exposure, there may be an imbalance between the body's defenses against free radicals and antioxidants, making the testis more susceptible to oxidative damage. This imbalance could potentially have a detrimental effect on the function of the male reproductive system.
    Preclinical • Journal • Adverse events • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CAT (Catalase)
    5d
    Proteomic serum profiles before and after lipoprotein apheresis in patients with peripheral artery disease with ulceration. (PubMed, Ther Apher Dial)
    Serum BAX and CXCL10 levels significantly decreased after LA, which may be involved in the ulcer epithelialization mechanism of LA, which potentially acts through angiogenesis promotion.
    Journal
    |
    CXCL10 (Chemokine (C-X-C motif) ligand 10)
    6d
    HIV-1 Viremia and Cancer Risk in 2.8 Million People: the South African HIV Cancer Match Study. (PubMed, Clin Infect Dis)
    Our findings underline the importance of sustained viral suppression for cancer prevention among PWH in South Africa.
    Journal
    |
    CD4 (CD4 Molecule)
    6d
    Combination of fruquintinib with venetoclax for the treatment of colorectal cancer. (PubMed, Oncol Res)
    Our study presents the justification for utilizing the fruquintinib and venetoclax combination in treating CRC. Venetoclax holds promise in being assimilated into anticancer medications for CRC.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Fruzaqla (fruquintinib)
    6d
    Lenalidomide regulates the CCL21/CCR7/ERK1/2 axis to inhibit migration and proliferation in diffuse large B-cell lymphoma. (PubMed, Oncol Res)
    In vivo experiments reinforced the efficacy of lenalidomide, significantly reducing tumor growth rate, tumor mass, serum total LDH levels, and expression of CCR7 and p-ERK1/2 in a SU-DHL-2 xenograft model in nude mice (p < 0.05). Our study clarifies the potential role of the CCL21/CCR7/ERK1/2 axis in the therapeutic effects of lenalidomide in DLBCL treatment.
    Journal
    |
    CCR7 (Chemokine (C-C motif) receptor 7) • CCL21 (C-C Motif Chemokine Ligand 21)
    |
    CCR7 expresion
    |
    lenalidomide
    8d
    The relationship between clinical prognostic factors, microvascular density, and tumor-infiltrating lymphocytes with CD47 and SIRPα expression in diffuse large B cell lymphomas. (PubMed, Leuk Res)
    The study reveals that increased CD47-SIRPα expression is partially linked to adverse prognostic indicators and reduced MVD in DLBCL cases. These findings suggest that targeting the CD47-SIRPα axis could offer a novel therapeutic approach in DLBCL, particularly for patients with poor prognostic features.
    Journal • Tumor-infiltrating lymphocyte
    |
    CD47 (CD47 Molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • SIRPA (Signal Regulatory Protein Alpha)
    |
    CD31 expression
    8d
    Splenic fibroblasts control marginal zone B cell movement and function via two distinct Notch2-dependent regulatory programs. (PubMed, Immunity)
    Key elements of the mouse B cell Notch regulome were preserved in subsets of human memory B cells and B cell lymphomas. Thus, specialized niches program the poised state and patrolling behavior of MZB cells via conserved Myc-dependent and Myc-independent Notch2-regulated mechanisms.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • NOTCH2 (Notch 2) • S1PR1 (Sphingosine-1-Phosphate Receptor 1)
    |
    MYC expression
    8d
    Revealing the heterogeneity of treatment resistance in less-defined subtype diffuse large B cell lymphoma patients by integrating programmed cell death patterns and liquid biopsy. (PubMed, Clin Transl Med)
    To identify robust prognostic biomarkers that can guide personalized management for less-defined subtype DLBCL patients, we integrated multi-omics data derived from 339 standard R-CHOP-treated patients diagnosed with less-defined subtype DLBCL from three independent cohorts...The difference in clinical characteristics, circulating tumour DNA burden and immune profiling between patients with distinct PCDI groups. A potentially effective regimen was speculated for patients with high PCDI scores who tend to exhibit worse progression-free survival.
    Journal • Liquid biopsy
    |
    FLT3 (Fms-related tyrosine kinase 3) • CD8 (cluster of differentiation 8) • BCL2L1 (BCL2-like 1) • SORL1 (Sortilin Related Receptor 1)
    |
    Rituxan (rituximab)
    9d
    Impact of C-MYC/BCL2 Double Expression on Survival Outcomes After Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma-A Nationwide Retrospective Analysis in Singapore. (PubMed, Hematol Oncol)
    No abstract available
    Retrospective data • Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2 expression • MYC expression
    9d
    waveLINE-010: A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) (clinicaltrials.gov)
    P3, N=1046, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Truxima (rituximab-abbs) • zilovertamab vedotin (MK-2140) • prednisolone
    9d
    Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P3, N=92, Active, not recruiting, National Cancer Institute (NCI) | N=302 --> 92 | Trial completion date: May 2025 --> Dec 2025 | Trial primary completion date: May 2025 --> Jun 2024
    Enrollment change • Trial completion date • Trial primary completion date
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • TNFA (Tumor Necrosis Factor-Alpha) • CARD11 (Caspase Recruitment Domain Family Member 11) • TNFAIP3 (TNF Alpha Induced Protein 3) • CD79A (CD79a Molecule) • GSTT1 (Glutathione S-transferase theta 1)
    |
    BCL2 expression • MYC expression • MYC translocation • CD79A mutation • CD79A mutation + CD79B mutation
    |
    Imbruvica (ibrutinib) • cytarabine • cyclophosphamide • etoposide IV • carmustine • melphalan • Starasid (cytarabine ocfosfate)
    9d
    MED20-165: Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=6, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026
    Trial completion date • Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD19 (CD19 Molecule)
    |
    CD19 expression
    |
    Iomab-ACT
    9d
    Dynamic CtDNA-guided Targeted Therapy in DLBCL (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide
    9d
    Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (clinicaltrials.gov)
    P4, N=50, Completed, Takeda | Active, not recruiting --> Completed
    Trial completion
    |
    Adcetris (brentuximab vedotin)
    9d
    CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) (clinicaltrials.gov)
    P2, N=34, Not yet recruiting, Ruijin Hospital
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • decitabine • Epidaza (chidamide)